Paul F. Lizzul bought stock once, on Aug 1, 2017

Paul F. Lizzul, MD, PhD, MPH, MBA, FAAD, is the Chief Medical Officer at AnaptysBio, Inc. (NASDAQ: ANAB), where he leads the development organization, overseeing clinical medicine, operations, regulatory affairs, pharmacology, and toxicology.( He joined AnaptysBio in 2020 and has been involved in advancing immunology therapeutics, including ANB032 for atopic dermatitis and imsidolimab for conditions like hidradenitis suppurativa and pustular psoriasis.(

Dr. Lizzul is a board-certified dermatologist with prior roles as Global Development Lead for Inflammation at Amgen, Chief Medical Officer at Sienna Biopharmaceuticals, and Senior Medical Director at Kythera Biopharmaceuticals.( Earlier, he served as Assistant Professor of Dermatology at Tufts Medical Center, conducted clinical research, and was a member of the FDA Dermatology and Ophthalmic Drugs Advisory Committee (2010-2012).( He earned his MD, PhD in molecular genetics, and MPH in epidemiology from Rutgers Robert Wood Johnson Medical School, completed dermatology residency at UC Davis, and holds an MBA in entrepreneurship from Rutgers Business School.( Recently, as a corporate insider, he sold 2,235 shares of ANAB stock on January 7, 2026.(

Written by Perplexity from public sources.